MYO18B and neoplasm: Accumulating data show that one of these HDAC inhibitors, TSA, can cause the reactivation of a number of tumor suppressor genes such as TGF-beta receptor type II [32], death-associated protein kinase [33], CCAAT/enhancer-binding protein α [34] and MYO18B [35] in lung cancer.